{
  "docId": "019de071-f648-72d0-9c84-3373768bf908",
  "docSlug": "15eb2f0f83943ed61260bacd75adb779",
  "documentTitle": "ATAI | Investor Day Presentation Deck | 42 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 42,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide uses a comparative analysis between cancer and schizophrenia/CIAS to highlight resource allocation disparities.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f648-72d0-9c84-3373768bf908/15",
  "deckHref": "/decks/019de071-f648-72d0-9c84-3373768bf908",
  "deckJsonHref": "/decks/019de071-f648-72d0-9c84-3373768bf908.json",
  "deckAnchorHref": "/decks/019de071-f648-72d0-9c84-3373768bf908#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.04,
        "y": 0.65
      },
      "kind": "callout",
      "text": "Curing cancer is more likely to be more personally tangible and may appear to be more morally compelling to investors",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6769b36b-db80-4cff-ab8a-94681f72a924",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.91,
        "x": 0.08,
        "y": 0.37
      },
      "kind": "list",
      "text": "NIH spend 25 times more on cancer than on schizophrenia\nIndustry investment in clinical trials in 2017 was $71.5 billion, dwarfs government efforts.\nThere are over 1,000 ongoing clinical trials in cancer for every one in CIAS\nProgress from phase 1 to the US Food and Drug Administration (FDA) approval is 5.1% for cancer indications, very similar to psychiatry at 6.2%.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e40cbe3e-07b1-4782-b78c-ffc8f4efc150",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.93,
        "x": 0.04,
        "y": 0.26
      },
      "kind": "paragraph",
      "text": "Amount of investment that is being made in the development of treatments and opportunities for success",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d6dee58-6500-4476-b230-56ebbd21f968",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.67,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "200+ CIAS treatment trials listed on Clinicaltrials.gov",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d1476d16-c762-463e-a2bd-f0fb79af90c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.82,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "Keefe RSE. Why are there no approved treatments for Cognitive Impairment in Schizophrenia? World Psychiatry, 2019; Jun; 18(2): 167-168. (PMID: 31059617).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fadf4cbd-3f23-4d4b-8535-c30e61cd2b3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Why Are There No Approved Treatments for CIAS?",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1e21ed5e-584c-4aa4-9d44-a069bf904851",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "0426f258-e9f6-4432-8a2f-e43c76ec2125",
      "evidence": "Compares CIAS metrics against cancer metrics to explain investment disparity.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 16,
      "from": 15,
      "beatId": "ef668d0a-0800-4ad1-a5b6-7beff2661f71",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Agitate (Make it worse)",
      "beatSlug": "problem-agitate-solution-agitate-make-it-worse",
      "evidence": "Slides 15-16 agitate the problem by highlighting the lack of approved treatments and the potential for RL-007 to address this need",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}